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Main points: Inhibition of glial DPP4 may provide a novel approach to pain management by induction or 
modulation of endogenous opioidergic systems. 
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2) ABSTRACT 
 
Altered pain sensations such as hyperalgesia and allodynia are characteristic features of various chronic pain 
states, and remain difficult to treat. We have shown previously that spinal application of dipeptidyl peptidase 4 
(DPP4) enzyme inhibitors results in a strong antihyperalgesic effect during inflammatory pain states. In this study 
we observed a low level of mRNA for DPP4 in the rat spinal dorsal horn in physiological conditions, which did 
not change significantly either in carrageenan-induced inflammatory or partial nerve ligation-generated 
neuropathic states. Although DPP4 protein was detected in neurons, astrocytes and microglia in naïve animals its 
expression significantly increased in astrocytes during inflammation and in microglia in neuropathic conditions. 
Intrathecal application of two DPP4 inhibitors the tripeptide isoleucin-prolin-isoleucin (IPI) and the antidiabetic 
drug vildagliptin resulted in robust opioid-dependent antihyperalgesic effect during inflammation and an opioid-
independent effect in the Seltzer model. The opioid-mediated antihyperalgesic effect of IPI was exclusively 
related to mu-opioid receptors, while vildagliptin affected mainly delta-receptor activity, although mu- and kappa-
receptors were also involved.  
Our results suggest a pathology and glia type specific changes of the DPP4 activity in the spinal cord which 
contributes to the development and maintenance of hyperalgesia and shapes opioid signalling. 
 
 
  
- 3 - 
 
3) TEXT 
Introduction 
Inflammation, nerve injury or ongoing diseases induce peripheral sensitization of primary sensory 
afferents and central sensitization of spinal neurons, resulting in hyperalgesia (increased response to noxious 
stimuli), allodynia (painful response to normally innocuous stimuli) and spontaneous pain (Sandkuhler 2009). 
Direct and specific interactions between primary afferents and spinal lamina I projection neurons are necessary 
for development of hyperalgesia (Khasabov et al. 2002; Nichols et al. 1999) and this involves Ca2+-dependent 
long term potentiation (LTP) in projection neurons via activation of NMDA and neurokinin-1 receptors (NK1R) 
following continuous release of glutamate and substance P (SP) from peptidergic C primary afferents (Sandkuhler 
and Gruber-Schoffnegger 2012). 
C fiber-related mu-opioid receptor (MOR) activation results in acute and reversible synaptic depression 
through inhibition of voltage-gated calcium channels and can reverse various forms of LTP, however prolonged 
application of MOR agonists and opioid withdrawal also leads to LTP and hyperalgesia (Heinke et al. 2011). 
Morphine hyperalgesia is mediated by microglia (Clark and Malcangio 2012; Ferrini and De Koninck 2013; Ji et 
al. 2013) and involves functional MORs (Laurie-Anne Roeckel et al 2017, Scientific Reports) Pronociceptive 
cytokines, such as interleukin-1β (IL-Iβ) and tumour necrosis factor (TNF), released from the microglia can affect 
the spinal synaptic transmission and contribution of microglia to LTP has also been demonstrated (Clark et al. 
2015; Gruber-Schoffnegger et al. 2013; Zhong et al. 2010). 
DPP4 is an integral membrane glycoprotein expressed on many cell types, but appears also in soluble form 
in body fluids including cerebrospinal fluid (Boonacker and Van Noorden 2003). As a serine protease, DPP4 
cleaves dipeptides from oligopeptides and proteins containing proline/alanine in the penultimate position. DPP4 
processes neuropeptides, hormones, cytokines and chemokines leading to their biological activation or 
inactivation. Potential substrates include bradykinin, glucagon-like peptide-1 (GLP-1) and -2, SP, neuropeptide 
Y (NPY), vasoactive intestinal polypeptide (VIP) and TNF-α (Mentlein 1999; Sakurada et al. 1999; Turner et al. 
1987). DPP4 is also known as cell surface antigen CD26 on T-lymphocytes (Gorrell et al. 1991; Yu et al. 2011) 
and receptor for Coronaviruses (Lu et al. 2013). Although only one type of DPP4 mRNA is detected (Hong et al. 
1989), molecular heterogeneity of the enzyme can result from posttranslational modifications (Kahne et al. 1996). 
DPP4 mRNA was detected in the brain of adult animals and its level did not change after cerebral 
ischemia. In contrast, DPP4 immunoreactivity was not found in the same regions in physiological state but 
appeared in neurons and glial cells during cerebral ischaemia (Rohnert et al. 2012). We demonstrated dramatic 
reduction of mechanical hyperalgesia following spinal application of DPP4 inhibitors in subacute inflammation 
and this action was naloxone reversible suggesting an opioid receptor-mediated effect. None of the inhibitors 
affected allodynia in inflammatory conditions or changed the nociceptive threshold in acute nociceptive tail-flick 
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test (Kiraly et al. 2009). Antihyperalgesic and anti-inflammatory effects of DPP4 inhibitors were also showed in 
chronic inflammatory models in mice (Ujhelyi et al. 2014). 
Machinery of the endogenous opioid system has been intensely investigated and clarified in recent 
decades. Although inducing/regulating the endogenous opioid machinery would provide a powerful tool to 
control pain propagation this possibility has remained largely unexploited. Here, we identify DPP4 in the spinal 
dorsal horn, show that its expression changes during pathological conditions, and demonstrate that it shapes opioid 
signalling in a receptor- and treatment-specific manner. Although synaptic DPP4 may have a key role in neuronal 
mechanisms of pain propagation, we identify glial cells as inducible DPP4-batteries, in this way playing a role in 
hyperalgesia and opioid signalling. 
 
Materials and Methods 
 
Animals 
Nociceptive threshold measurements were carried out on male Wistar rats weighing 170–230 g and 
received from the breeding colony of the Semmelweis University that were used for carrageenan induced 
hyperalgesia model, or on animals weighing 100–160 g at the start of the partial sciatic nerve ligation experiments 
(Seltzer model) and obtained from Charles River Laboratories via Innovo Ltd. (Gödöllő, Hungary) or Toxi-Coop 
Ltd. (Budapest, Hungary). These later groups were bred and kept at the Laboratory Animal Centre of the 
University of Pécs. Rats were housed under similar conditions both at Semmelweis University and University of 
Pécs including temperature-controlled rooms with 12 h light / 12 h dark cycles and standard rodent chow and tap 
water supplied ad libitum. 
Experiments were performed in accordance with the European Communities Council Directive 
86/609/ECC and were approved by the Committees on Animal Experiments of the Semmelweis University, 
Budapest (XIV-I-001/2265-4/2012) and the Medical School of the University of Pécs (BA02/2000-9/2011) 
Hungary. 
Drugs 
Diprotin A (isoleucin-prolin-isoleucin, IPI; Sigma-Aldrich, I9759) stock solution was made up in 25% 
(w/v) hydroxypropyl-beta-cyclodextrin (HPβCD, Sigma-Aldrich, H107) and dilutions were made with sterile 
saline and administered intrathecally (i.t.) in 30 nmol/rat dose. vildagliptin (VIL) was received from Prof. Ingrid 
De Meester of the Laboratory of Medical Biochemistry, University of Antwerp, Wilrijk, Belgium and was 
administered i.t. in 3 nmol/rat dose. Naltrexone hydrochloride (NTX) was a generous gift from DuPont 
Pharmaceuticals (Geneva, Switzerland), and was injected subcutaneously (s.c.) in 0.5mg/g b.w. dissolved in 
saline. 
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The MOR antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; Sigma-Aldrich, C6352; 200 
pmol/rat), delta-opioid receptor (DOR) -antagonist H-Tyr-Tic(CH2NH)-Phe-Phe-OH (TIPP[Ψ]; Sigma-Aldrich, 
T7075; 1 nmol/rat) and kappa-opioid receptor (KOR) -antagonist 5'-guanidinonaltrindole (gNTI; Sigma-Aldrich, 
G3416; 10 nmol/rat) were dissolved in distilled water. 
I.t. injections were delivered in 5μl volume by a 250μl Hamilton syringe set into a Hamilton dispenser. 
The 23-Ga needle was introduced at the L5-6 intervertertebral space (Kiraly et al. 2011; Kiraly et al. 2009). 
 
Behavioural experiments 
 
Carrageenan-induced subacute inflammation and hyperalgesia. Hyperalgesia was induced by intraplantar 
injection of 100μl l% λ-carrageenan dissolved in saline (Sigma-Aldrich, 22049) into the right hindpaw. 
Nociceptive threshold to pressure was determined by the Randall-Selitto method (Kiraly et al. 2011; Kiraly et al. 
2009; Randall and Selitto 1957) using a type 37215 Analgesy-Meter (Ugo Basile, Comerio, Italy). Rats were 
lightly restrained and an evenly increasing force was applied onto their paws inserted between the cone-shaped 
clamps of the apparatus. At the moment of paw withdrawal, the actual force was recorded as the nociceptive 
threshold. The baseline nociceptive threshold was initially determined on both hindpaws (at -5 min), then 
carrageenan was injected into the right hindpaw (at 0 min). The nociceptive threshold was measured again at 
180 min and i.t. injection of vehicle, DPP4 inhibitors alone (IPI or VIL) or in combination with subtype specific 
opioid receptor antagonists (CTAP, TIPP[Ψ] or gNTI), was performed. Nociceptive threshold readings were 
repeated at 185, 195, 210 and 240 minutes. Five rats were involved in each vehicle experiment, while for drug 
and drug combinations, 7–10 animals were used. 
Time-matching data sets on different ipsilateral curves were compared with two-way repeated measures 
ANOVA followed by Bonferroni post hoc test. Percentage maximum possible antihyperalgesic effects were 
calculated according to the following equation: MPE (%) = 100 x (ipsilateral threshold 30 min after i.t. drug 
application – hyperalgesic baseline) / (contralateral threshold at the same time – hyperalgesic baseline), where 
hyperalgesic baseline was defined as the nociceptive threshold of the inflamed hindpaw 180 min after intraplantar 
carrageenan injection, then comparisons were made with one-way ANOVA followed by Dunnett’s post hoc test 
(Kiraly et al. 2011; Kiraly et al. 2009). 
 
Partial sciatic nerve ligation-induced chronic neuropathic pain model (Seltzer model). Baseline 
nociceptive thresholds were determined on two consecutive days using three different methods: dynamic plantar 
aestesiometry (DPA, mechanical allodynia), noxious cold stimulation (cold allodynia) and Randall-Selitto test 
(mechanical hyperalgesia). Under deep pentobarbital anesthesia (50 mg/kg i.p. Euthasol, Produlab Pharma, 
Raamsdonksveer, Netherlands), the sciatic nerves of rats (n=100) were tightly ligated high in the thigh unilaterally 
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using a braided silk suture (Mersilk 6-0, Ethicone) so that approximately 1/3–1/2 of the diameter of the nerve was 
trapped in the ligature (Seltzer et al. 1990). The wound was closed afterwards with 4-0 silk sutures and the animals 
were allowed to recover for one week. 
On the 7th postoperative day, nociceptive threshold measurements were repeated for each animal at short 
intervals and percentage hyperalgesia/allodynia values were calculated for the nerve-injured paws with the 
following formula: hyperalgesia/allodynia (%) = 100 x (preoperative – postoperative values) / (preoperative 
values). Only animals that developed a minimum of 20% decrease of threshold with each method were included 
in treatment groups (n=71). Rats were arranged into groups having similar degree of hyperalgesia/allodynia and 
received (1) i.t. vehicle or (2) DPP4 inhibitor or (3) DPP4 inhibitor 15 min after s.c. NTX pretreatment. For i.t. 
vehicle and DPP4 inhibitor experiments, 8-10 animals were used in each group, while groups undergoing i.t. 
DPP4 inhibitor application following s.c. NTX pretreatment consisted of 5-8 rats. Nociceptive measurements 
from each animal were carried out 20-30 min after i.t. injection starting with DPA at 20 min, followed by Randall-
Selitto test at 25 min and finishing with noxious cold stimulation at 30 min. During dynamic plantar 
aesthesiometry rats were placed into an observation chamber positioned on a metal mesh surface. The touch 
stimulator unit was placed under the animal’s paw and increasing upward force (10 g/s) was exerted until the rat 
removed its paw. Withdrawal thresholds were measured 3 times in turns for each hindpaw and the mean values 
were used for statistical analysis. If no withdrawal occurred, the preset maximum (50 g) was used in the 
evaluation. Randall-Selitto test was performed as detailed above. To measure noxious cold sensitivity, hindpaws 
of lightly restrained rats were immersed into a 0°C water bath and the latency to paw withdrawal was recorded. 
The cut-off time was set to 180 seconds. 
Withdrawal thresholds recorded before nerve ligation, then on the 7th postoperative day before and after 
drug applications were compared with two-way repeated measures ANOVA followed by Bonferroni post hoc 
test. Percent maximum possible effects were calculated according to the following formula: MPE (%) = 100 x 
(withdrawal threshold after drug application – withdrawal threshold before nerve ligation) / (withdrawal threshold 
before drug application – withdrawal threshold before nerve ligation), then comparisons were made with one-
way ANOVA followed by Dunnett’s post hoc test. 
 
RNA isolation and real-time PCR analyses 
Carrageenan was injected into both hindpaws of 6 rats and partial ligation of both sciatic nerves was 
performed in 9 animals. Survival time was 3 hours and 7 days, respectively. Development of inflammatory or 
neuropathic hyperalgesia was confirmed by the Randall-Selitto test, and then rats were sacrificed by decapitation, 
with a further 6 animals used as controls. L4-L6 spinal segments were removed and frozen on dry ice. RNA was 
isolated using the RNeasy Lipid Tissue Mini Kit (QIAGEN) from spinal cord samples according to the 
manufacturer's instructions. The purity and concentration of the RNA were analyzed using a SmartSpec Plus 
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spectrophotometer (Bio-Rad, UK). Reverse transcription was performed with 1 μg of RNA to convert the total 
RNA to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems by Life 
Technologies). Concentration of the generated cDNA was determined using the Qubit 2.0 Fluorometer with the 
Qubit ssDNA Assay Kit (Life Technologies). Expression of DPP4 mRNA was measured by real-time quantitative 
TaqMan RT-PCR reaction with a ViiA 7 Real-Time PCR System (Life Technologies), using commercially 
available TaqMan probe (Rn00562910_n1) on 10-ng cDNA template in duplicates. Glyceraldehyde-3-phosphate 
dehydrogenase (Rn99999916_s1) was used as a housekeeping gene, and its expression did not vary between the 
experimental groups. 
For statistical analyses, qPCR data were expressed as relative quantification values (RQ; mean ± SEM) 
and compared between groups by one-way ANOVA. 
 
In situ hybridisation 
The 1632-2051 bp long fragment of the rat DPP4 cDNA (gene bank accession #NM_012789) was 
purchased from Blue Heron Biotechnology Inc. (Bothell, WA, USA), subcloned into pBC KS+ (Addgene, 
Cambridge, MA, USA) vector, and verified by sequencing. In situ hybridisation (ISH) was performed as described 
earlier (Toth et al. 2008). Riboprobes in sense and antisense directions were prepared by in vitro transcription 
(MAXIscriptKit, Life Technologies, Carlsbad, CA, USA) and labelled using [35S]UTP-(Per-Form Hungaria Kft, 
Budapest, Hungary). Carrageenan was injected into both hindpaws of 3 rats and partial ligation of both sciatic 
nerves was performed in 3 animals. Survival time was 3 hours and 7 days, respectively. Development of 
inflammatory or neuropathic hyperalgesia was confirmed by the Randall-Selitto test, and then rats were sacrificed 
by decapitation, with a further 3 animals used as controls. The spinal dorsal horn of L4-L6 segments were removed 
and frozen on dry ice. Serial coronal sections were cut in a cryostat and mounted onto positively charged 
Superfrost Plus slides (Life Technologies). Slides were hybridized overnight in humid chambers at 55C with 
106 cpm/slide of the radioactively labelled probes, washed and dehydrated. Slides were dipped into NTB nuclear 
track emulsion (Carestream Health Deutschland GmbH, Stuttgart, Germany) for 4 weeks. Emulsion-coated slides 
were developed using Kodak Dektol developer and Fixer (Sigma-Aldrich Kft, Budapest, Hungary). Sections were 
counter-stained with 0.5% Giemsa solution (Sigma), air dried and coverslipped using Depex mounting medium. 
Dark-field images of three samples per animal were captured by a BX51 Olympus microscope (Olympus 
Corporation, Hamburg, Germany) attached to a QICAM (Qimaging, Surrey, BC, Canada) camera. The grain 
density indicating the level of the DPP4 mRNA expression was calculated as the area percent occupied by the 
silver grains within a given region of interest (ROI; 100x100 pixel2) using the Image J 1.32j program. In each 
section, 3 ROIs from the background (area outside of the tissue) and 5 ROIs from the dorsal horn were measured 
and averaged. Then the background was subtracted from the value that was obtained from the tissue. The sense 
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and antisense signals were compared using Student’s t-tests with SigmaStat 3.5program (Systat Software, Inc. 
San Jose, CA, USA). One way ANOVA was used for comparing the antisense in situ hybridization signals among 
the groups. 
Western blotting 
Five rats with unilateral carrageenan-induced hindpaw inflammation, 9 rats undergoing unilateral partial 
nerve ligation one week earlier with further 4 naïve rats were tested with the Randall-Selitto method as it was 
described above. After confirming the obvious decrease of nociceptive thresholds, animals were sacrificed by 
decapitation, and the spinal dorsal horn of L4-L6 segments were removed and snap-frozen on dry ice. Samples 
were homogenized in TNE buffer containing 0.5% Triton X-100 (Sigma), 5 mM NaF, 100 μM Na3VO4 and a 
cocktail of protease inhibitors (CompleteTM, Roche) and briefly sonicated. Cell debris and nuclei were pelleted 
by centrifugation (800g, 30 min at 4°C). Protein concentrations were determined by Bradford’s colorimetric 
method (Bradford 1976). Samples were diluted to a final protein concentration of 2 μg/μl, denatured in 5x 
Laemmli buffer, and analysed by SDS-PAGE on a 10% resolving gel. After transferring onto Immobilon-FL 
polyvinylidene difluoride membranes (Millipore), membrane-bound protein samples were blocked in 3% BSA 
and 0.5% Tween-20 diluted in TBS for 1.5h, and subsequently exposed to the goat DPP4 primary antibody (Table 
1.) overnight at 4 °C. Signal detection was achieved by using a HRP-conjugated donkey anti-goat secondary 
antibody (Jackson; 1:10,000). Image acquisition and analysis were performed on a Bio-Rad XRS+ imaging 
platform. 
 
Immunofluorescent labelling 
Antibodies 
Polyclonal goat DPP4 antibody was raised against the synthetic peptide C-PPHFDKSKKYP representing 
the internal region of DPP4 according to NP_001926.2 and labelled one band at approx. 110 kDa in rat lung lysate 
in Western blot experiments (for details see the supplier’s datasheet). In our Western blot experiments rat lung 
and pancreas lysates were used as positive controls (Fig. 1C). Monoclonal mouse DPP4 antibody was produced 
against the full length rat CD26 protein. To test the specificity of the two DPP4 antibodies double 
immunofluorescent staining was carried out (Lorincz and Nusser 2008). Both antibodies labelled the same profiles 
in neurons, astrocytes and microglia (Fig. 2). 
Mouse anti-neuron-specific nuclear protein (NeuN) was used for labelling neuronal somata (Todd et al. 
1998) together with NeuroTrace 435/455 blue-fluorescent Nissl stain (Pap et al. 2015) (Thermo Fischer Scientific 
- Invitrogen, Cat#: N-21479; 1:200). Dendrites were identified with monoclonal mouse antibody produced in 
mice against microtubule-associated protein 2 (MAP2) (Attems et al. 2012; Binder et al. 1986). Antibody stained 
one single lane at 280 kDa in Western blot experiment using rat brain extract. Ionized calcium-binding adaptor 
molecule-1 (IBA1) was used as specific microglia/macrophage marker and anti-IBA1 antibody was isolated from 
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the serum of rabbits immunized with a synthetic peptide corresponding to C-terminus of IBA1. According to the 
provider antibody stains one single lane in Western blot experiments at around 17 kDa. Monoclonal mouse 
antibody against glial fibrillary acidic protein (GFAP) was used for specific labelling of astrocytes. Guinea pig 
antibody against vesicular glutamate transporter 2 (VGLUT2) was used to identify excitatory axon terminals. The 
antibody is raised against a 18 amino acid long sequence of the rat protein and Western blot analysis on rat brain 
lysate showed 52kDa lane as it is seen on the provider’s datasheet related to Lot#: NG1866937. This VGLUT2 
antibody is heavily used and well characterized (Ganley et al. 2015). Inhibitory boutons were labelled with 
polyclonal antibodies against vesicular GABA transporter (VGAT) raised in rabbits immunized by the synthetic 
peptide AEPPVEGDIHYQR (amino acids 75-87 in rat VGAT) coupled to key-hole limpet hemocyanin via an 
added N- terminal cysteine. Based on the supplier’s data sheet this antibody is knock-out verified. Synaptophysin 
(SYN) was used as a synaptic marker and monoclonal mouse antibody was raised against synthetic peptide 
corresponding to a region near to the C-terminal end of the full peptide. SYN antibody validation by 
immunohistochemistry and Western blot is found in the Human Protein Atlas (http://www.proteinatlas.org). 
Calcitonin gene-related peptide (CGRP) antibody raised in guinea pig and used for labelling peptidergic 
unmyelinated primary afferents recognizes identical structures to those detected by well characterized rabbit and 
goat antibodies against rat α-CGRP (Kozsurek et al. 2007). For detailed specifications of antibodies see Table 1. 
Secondary antibodies were all raised in donkey: Alexa Fluor (AF) -488 labelled anti-goat, AF-555 
conjugated anti-mouse, AF-555 labelled anti-rabbit (all from Thermo Fischer Scientific-Invitrogen-Molecular 
Probes; 1:500) and Rhodamine Red X-anti guinea pig, Cyanine 5-anti mouse, Cyanine 5-anti rabbit (all from 
Jackson ImmunoResearch; 1:100). 
 
General immunofluorescent staining protocol 
Transcardial perfusion of deeply anesthetized (75 mg ketamine and 7.5 mg xylazine; i.m.) rats (5 naive, 5 
unilateral carrageenan treated, and 5 unilateral nerve ligated as described above) was initiated with 4% 
(para)formaldehyde and completed with 4% (para)formaldehyde containing 10% sucrose. L4-L5 spinal segments 
were removed and immersed overnight into 20% sucrose dissolved in PBS. Segments were frozen with liquid 
nitrogen and then 50 µm thick sections were cut on a Vibratome. Endogenous peroxidase activity was blocked 
for 30 minutes with 1% hydrogen peroxide diluted in phosphate buffer (PB), then sections were transferred into 
phosphate buffered saline (PBS) with 5% normal horse serum (NHS). After the blocking procedure they were 
incubated overnight in the DPP4 antibodies then reacted with Alexa Fluor 488 labelled species specific secondary 
antibodies. Sections were incubated for 72 hours in mixtures of the other primary antibodies and were reacted 
overnight with fluorescently labelled species specific secondary antibodies. All the primary and secondary 
antibodies were dissolved in PBS. In some sets of experiments, sections were immersed into Neurotrace 
fluorescent Nissl dye (Invitrogen-Molecular Probes; 1:200 in 0.1M phosphate buffer) for half an hour before 
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mounting. After rinsing, sections were mounted in Vectashield (Vector Laboratories) and scanned on a confocal 
laser scanning system (Zeiss, LSM780). 
 
Densitometry of DPP4 immunostaining 
L4 and L5 spinal cord segments taken from 5 control, 5 carrageenan-treated and 5 nerve-ligated rats were 
used for quantitative analysis. Three to six spinal cord sections were taken from each segment on the basis of the 
gray matter shape and 5 to 8 confocal optical sections were scanned from each section. DPP4 staining was not 
viewed prior to selecting any sections, ROIs or cell profiles. The quantitative analysis was carried out by an 
independent observer, who was blind to the experimental conditions and was not involved in the scanning either. 
To determine DPP4 immunoreactivity and its alteration under different circumstances fields containing 
the whole dorsal horn were scanned through a 20x lens of the confocal microscope to produce z-stacks with z 
separation of 1 µm. The scanning parameters were selected and optimized in sections from control animals and 
were used further in sections of treated rats. Single optical sections containing black and white images were 
selected from each z-series and analysed using the Image J program (Rasband WS, Image J, NIH, Bethesda, 
Maryland). The medial two third of the dorsal horn containing the first four laminae (the area receiving inputs 
from the sciatic nerve) was drawn in each section and used as region of interest (ROI). The threshold was adjusted 
and the density of the immunostaining was calculated as the area percentage occupied by the immunostained dots 
within a given ROI. Data were compared among groups by one-way ANOVA. 
To analyse the density of the DPP4 immunoreactivity in individual cell types, non-overlapping fields of 
135 µm x 135 µm within the medial two third of the spinal dorsal horn were scanned through a 63x oil immersion 
lens to generate z-stacks with a z-separation of 0.5 µm. The same optimized parameters were used for all types 
of sections. IBA1-, GFAP- and DPP4-immunolabellings (for glial cells) or DPP4 immunolabelling with 
fluorescent Nissl staining (neuronal cell bodies) were imaged in different colour channels sequentially. Outlines 
of microglia and astrocytes were determined automatically by using the AutoThreshold plugin of ImageJ in IBA1 
and GFAP image channels, respectively. To exclude non-specific labelling of glial cells and nuclei by the 
fluorescent Nissl dye, contours of randomly selected neurons (8 neuron/field) were drawn manually. Then 
integrated density values from DPP4 image channel were measured in previously delineated glial or neuronal 
profiles to detect changes in protein expression due to different treatments. The density values were subjected to 
statistical analysis.  
 
 
 
Statistical analysis 
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Statistical methods used are detailed at each experiment individually. Analyses were made with SigmaStat 
3.5program (Systat Software, Inc. San Jose, CA, USA) and curves/bar graphs were created with the GraphPad 
Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). In general, data were represented as 
mean±SEM when the population was normally distributed or as median with 25% and 75%, otherwise. In both 
cases, p<0.05 was considered as statistically significant. 
 
Results 
 
DPP4 transcripts in the rat spinal dorsal horn in physiological, inflammatory and neuropathic states 
Taqman qPCR detected DPP4 mRNA in the dorsal horn of L5 spinal segments taken from control, 
inflamed and neuropathic rats. Neither carrageenan treatment nor neuropathic condition caused significant 
alteration in the DPP4 mRNA levels (control vs. carrageenan-induced inflammation vs. neuropathy (RQ): 1.0±0.2 
vs. 0.7±0.1 vs. 1.3±0.3, one-way ANOVA P=0.301; Fig. 1. A). 
DPP4 mRNA showed a low expression by in situ hybridization in the spinal dorsal horn of L4-L6 
segments. While the grain density observed in sections hybridized using the sense probe was equal to the 
background, a significant signal was detected with the antisense probe (antisense: N=27, median=110.4, 25% at 
80.7 and 75% at 135.5; sense: N=19, median=0, 25% at 0, 75% at 21.7; Mann-Whitney Rank Sum Test p<0,001). 
DPP4 mRNA was distributed evenly within the dorsal horn, and no significant difference among the experimental 
groups has been detected (control: N=9, 1.2±0.2; inflamed: N=9, 1.1±0.1; neuropathic: N=9, 1.0±0.1; one-way 
ANOVA, p=0,21; Fig. 1. B). 
 
DPP4 protein expression in physiological condition and its changes during inflammation and neuropathy 
in the spinal dorsal horn 
Western-blot analysis demonstrated an elevated protein level in the inflamed spinal cord being 
significantly different from those found in naïve and neuropathic spinal cords (control: N=4, 0.16±0.05; inflamed: 
N=5, 0.54±0.06; neuropathic: N=9, 0.31±0.06; one-way ANOVA, Holm-Sidak method, p=0,023; Fig. 1. C, E). 
DPP4 immunoreactivity in the spinal cord appeared in naïve, inflamed and also in neuropathic animals. 
Immunostaining for the enzyme was weaker in the superficial laminae than in the deeper laminae in control and 
neuropathic conditions but increased significantly in the medial two third of the dorsal horn during inflammation 
(Fig. 1 D). Densitometry of the DPP4 immunolabelling showed a significant increase in inflamed spinal cord in 
those areas corresponding to the inflamed hind paw compared to naïve and neuropathic conditions (control: N=7, 
3.42±0.38; inflamed: N=10, 5.66±0.80; neuropathic: N=8, 3.18±0.44; one-way ANOVA p=0,016; Fig. 1. F). 
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DPP4 immunoreactivity and its changes in individual cell types during pathology 
Punctate-like immunostaining was detected in neuronal cell bodies (Fig. 2. A) and also in axon terminals 
in naive animals. Puncta representing DPP4 were embedded in synaptophysin stained elements suggesting close 
relationship between synaptic and DPP4 activity in many cases (Fig. 3.). DPP4-immunopositive dots that 
appeared on MAP2 labelled dendrites were always associated with synaptophysin positivity (Fig. 3. A) suggesting 
that dendrites did not express the enzyme but received synapses from DPP4-containing boutons. The enzyme 
appeared both in vesicular glutamate transporter 2 (VGLUT2) immunolabelled excitatory (Fig. 3. C) and in 
vesicular GABA transporter (VGAT) positive inhibitory axon terminals (Fig. 3. D), as well as in CGRP stained 
primary afferent boutons (Fig. 3. B). DPP4 labelling also occurred in GFAP-positive astrocytes (Fig. 2. B) and 
IBA1-stained microglia cells (Fig. 2. C). In naive rats, the density of the enzyme staining was the highest in 
astrocytes and differed significantly from that in other cell types. DPP4 density was also significantly higher in 
microglia than in neurons (astrocyte: N=109, median=18652.86, 25% at 8185.077, 75% at 31208.903; microglia: 
N=83, median=3196.484, 25% at 2338.702, 75% at 5189.725; neuron: N=96 median=343.95, 25% at 247.461, 
75% at 420.691; Kruskal-Wallis one-way ANOVA on ranks, Dunn’s method at P<0.001). During inflammation, 
DPP4 expression increased significantly in astocytes but not in microglia and neurons. Significant increase in the 
DPP4 immunoreactivity appeared only in microglia and significant decrease in neurons in the Seltzer model 
(astrocyte control: N=109, median=18652.86, 25% at 8185.077, 75% at 31208.903, infl.: N= 112, 
median=33379.275, 25% at 7651.471, 75% at 43072.64, Seltzer: N= 80, median=15583.715, 25% at 8802.536, 
75% at 22288.04, Kruskal-Wallis one-way ANOVA on ranks, Dunn’s method at P<0.001; microglia control: 
N=83, median=3196.484, 25% at 2338.702, 75% at 5189.725, infl.: N= 86, median=2996,707, 25% at 2446.597, 
75% at 4359.576, Seltzer: N=67, median=4926.802, 25% at 3312.321, 75% at 6493.72, Kruskal-Wallis one-way 
ANOVA on ranks, Dunn’s method P<0.001; neuron control: N=96, median=343.95, 25% at 247.461, 75% at 
420.691, infl.: N=64, median=312.079, 25% at 203.529, 75% at 416.453, Seltzer: N=64 median=278.455, 25% 
at 213.089, 75% at 362.673, Kruskal-Wallis one-way ANOVA on ranks, Dunn’s method at P<0.001, in all cases 
N means the number of the analysed optical sections of neuronal or glial elements). It should be noted that DPP4 
immunolabelling existed not only in the membranes of the different cell types but also in intracellular 
compartments (Fig. 4 .A, B, C). 
 
Opioid receptor types involved in the antihyperalgesic effect of DPP4 inhibitors in inflammation 
To challange the involved opioid receptor types, selective opioid receptor antagonists were applied 
spinally together with two different DPP4 inhibitors in carrageenan-induced subacute inflammation. I.t. 
application of 30 nmol/rat IPI and 3 nmol/rat vildagliptin eliminated 93.8±1.2% and 88.3±1.6% of mechanical 
hyperalgesia measured by the Randall-Selitto test in intraplantar carrageenan-induced inflammation. Co-
administration of the mu-selective inhibitor CTAP reduced the antihyperalgesic effect of IPI to -5.0±4.5%, while 
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following co-application of kappa-receptor antagonist gNTI and the delta-opioid antagonist TIPP[Ψ] the 
antihyperalgesic effect of IPI remained at 92.2±2.4% and 90.1±3.0%, respectively. Following co-administration 
of mu- and kappa-antagonists, antihyperalgesic effect of vildagliptin was 51.0±4.4% and 45.8±4.2%, respectively, 
while the delta-antagonist TIPP[Ψ] completely blocked the antihyperalgesic effect of vildagliptin by reducing its 
antihyperalgesic effect to -1.4±2.1% (Fig. 5.). 
 
 
Effects of DPP4 inhibitors in neuropathy 
Different modalities of hyperalgesia and allodynia appear not only in inflammatory conditions but also in 
neuropathic pain states. None of the tested DPP4 inhibitors had significant effect on mechanical and cold 
allodynia, while both i.t. IPI and Vildagliptin had an obvious mechanical antihyperalgesic effect measured with 
the Randall-Selitto test one week after partial sciatic nerve ligation with MPE values of 37.9±12.4% and 
41.8±10.4%, respectively. In contrast to inflammatory states, NTX did not affect the antihyperalgesic action of 
the DPP4 inhibitors signifficantly in neuropathic conditions suggesting completely different actions of the enzyme 
on hyperalgesia in the two pain states. (Fig. 6.). 
 
Discussion 
 
DPP4 expression in the spinal dorsal horn 
A high level of DPP4 expression in the developing brain and spinal cord was described, which 
dramatically decreased in adults, remaining in leptomeningeal cells and capillary endothelial cells of the choroid 
plexus (Bernstein et al. 1987; Haninec and Grim 1990; Mitro and Lojda 1988). DPP4 mRNA was detected in 
cortical areas in adult naïve animals and its level did not change after cerebral ischemia. In contrast, DPP4 
immunoreactivity was not found in the same regions in physiological state but its expression appeared in 
microglia, neurons and astrocytes in different time points during cerebral ischaemia (Rohnert et al. 2012). We are 
first to show that transcripts as well as the protein of DPP4 are detectable in the mammalian spinal dorsal horn. 
Similarly to ischemic injuries in the brain, our q-PCR and in situ hybridization analysis showed that DPP4 mRNA 
level remained similarly low in inflammation or neuropathy compared to physiological state. At the same time, a 
significant shift was experienced at the protein level in the investigated spinal cord, reflecting a five-fold increase 
in DPP4 protein expression and suggesting the posttranscriptional control of DPP4 expression during quickly 
developing inflammation and ischemia in neurons and glia. Our understanding of DPP4 molecular regulation is 
far from being complete. Studies on lymphocytes have demonstrated that while retinoic acid and interferon 
administration result in DPP4 transcription, IL12 upregulates DPP4 translation only and TNFα merely decrease 
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cell surface expression (Rohrborn et al. 2015; Zhong et al. 2015). Further studies are necessary to discover the 
molecular machinery that drives changes in DPP4 expression in the CNS during pathological states. 
High resolution confocal laser scanning imaging revealed that neuronal DPP4 was typically confined to 
presynaptic, and also to somatic domains, with significantly decreased densities in neuropathy. In contrast, 
astrocytes were amply decorated with DPP4-immunoreactive profiles, with significantly increasing density in 
inflammatory but not neuropathic states. Finally, a third-party involvement in spinal neuropathic mechanisms was 
likely reflected by the increase of DPP4 expression in microglia which showed an obvious protein expression 
level in control animals, too. 
Detectable levels of the DPP4 protein in healthy dorsal spinal cord, in contrast to brain tissue, could be 
due to the quick on-demand regulatory role of the moonlight protein in nociceptive processes where SP and NPY 
offer ample and typical substrates for DPP4. The presynaptic location of DPP4 in neurons suggests a possible 
role for this protein in synaptic physiology. On the other hand, glial expression of DPP4 which is significantly 
upregulated in a pathology and cell type specific manner opens further aspects to detect alternative roles of this 
protein in chronic pain states.  
  
Antihyperalgesic effect of the DPP4 inhibitors 
Previously, we have demonstrated that DPP4 inhibitors do not change the nociceptive threshold in acute 
nociceptive condition (Kiraly et al. 2009). In contrast to this, robust antihyperalgesic effects of different DPP4 
inhibitors such as IPI, vildagliptin and sitagliptin in carrageenan-induced and CFA-provoked chronic 
inflammatory models have been reported previously (Kiraly et al. 2011; Ujhelyi et al. 2014). The antihyperalgesic 
action of IPI and vildagliptin appeared opioid-mediated since the general opioid receptor antagonist NTX reversed 
their effects (Kiraly et al., 2009; Kiraly et al., 2011). In this study, we examined the opioid receptors involved by 
using selective antagonists against MOR, DOR, and KOR and measuring mechanical hyperalgesia in 
carrageenan-induced acute inflammation. Surprisingly, the antihyperalgesic effect of the IPI exclusively related 
to MOR, while vildagliptin affected mainly DOR but had also effect on MOR and KOR. It has been demonstrated 
previously that IPI does not activate MORs directly (Ronai et al. 1999). Both IPI and vildagliptin are inhibitors 
of the DPP4 but IPI with a penultimate proline is also a substrate of the enzyme and its competitive inhibition is 
a kinetic artefact (Rahfeld et al. 1991). Although both inhibitors target the active site of the enzyme, the extent of 
inhibition depends on the residual interaction between drug and active site residues. X-ray crystallography 
analysing the co-crystal structure of different inhibitors with DPP4 demonstrated that the inhibitors, but not the 
substrates could bind well beyond the S2 subsite to increase their inhibitory activity.  (Nabeno et al. 2013). Taking 
all these together supports that different residual interactions of the two inhibitors can affect the DPP4 activity in 
different ways. 
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Endogenous opioids, especially enkephalins, dynorphins and endorphins, are released from spinal and 
supraspinal sites during acute inflammation, but are degraded very quickly by extremely high enzymatic activity 
(Chen and Marvizon 2009). A common feature of these opioids is that they can activate each opioid receptor with 
different potencies. Since both IPI and vildagliptin are very selective DPP4 inhibitors, it is very unlikely that it 
has inhibitory effect on opioid degrading enzymes. On the other hand, it has been demonstrated that glial cells 
express opioid receptors and can synthesize endogenous opioids (Fan et al. 2015; Ruzicka and Akil 1997; Ruzicka 
et al. 1995). These processes are at least partly regulated by inflammatory mediators including IL-1β (Ruzicka 
and Akil 1997). The interaction between the two systems is mutual, since the endogeneous opioids also have 
effect on the production of inflammatory mediators released by glial cells (Finley et al. 2008).  
GLP1 receptor activation results in β-endorphin release from microglia and blocks inflammatory 
nociception and mechanical allodynia in the spinal nerve ligation model (Fan et al. 2015; Gong et al. 2014). In 
this study, we have found an increase in the expression of DPP4 both in microglia and astrocytes that can facilitate 
the degradation of many peptides including GLP1. Systemic increase of GLP-1 peptide has been detected during 
inflammation (Kahles et al. 2014) and IPI/vildagliptin blocking DPP4 activity may increase further the GLP1 
level in the spinal cord and induce β-endorphin release from microglia. 
In this study, we have found a substantial increase in the expression of DPP4 in astrocytes during 
inflammation. It has been also demonstrated that astrocytes can synthesize both proenkephalins and dynorphins 
(Batter et al. 1991; Wahlert et al. 2013) that makes them good candidates for the source of these peptides. It has 
been shown that purinergic and toll-like receptor (TLR) activation results in dynorphin-A and -B releases from 
this glia type (Wahlert et al. 2013) and proenkephalin release was also detected in cultured astrocytes (Batter et 
al. 1991). However, the conditions in which astrocytes release proenkephalin in vivo have not been determined.  
Recent in vitro studies in monocytes demonstrated that DPP4 inhibitors suppressed TLR4 mediated 
upregulation of proinflammatory cytokines including IL-1β, IL-6 (Ta et al. 2011), NLRP3 inflammasome which 
is a key molecule to process and release of IL-1β and IL-18 (Dai et al. 2014), and extracellular-regulated kinase 
(ERK) activation that has also critical role in expression of inflammatory cytokines (Ta et al. 2010). These data 
suggest an important interaction between TLR4 and DPP4 activity which may exist also in glial cells and regulates 
the synthesis and release of inflammatory mediators and endogenous opioids. 
IPI and vildagliptin both produced a significant decrease in mechanical hyperalgesia in the Seltzer model 
but this effect was not opioid dependant. In addition to the mechanical hyperalgesia, mechanical and cold 
allodynia also appeared in this model. None of the inhibitors affected either types of allodynia. Our results indicate 
the contribution of the DPP4 enzyme to the development and maintenance of mechanical hyperalgesia in this 
model of neuropathy, but the underlying mechanisms are not known. The increased expression of the enzyme 
was most obvious in microglia suggesting their role in this process. The contribution of microglia to the 
development of allodynia in neuropathic condition is intensively studied (Beggs et al. 2012; Ferrini and De 
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Koninck 2013; Tsuda 2016), but its role in the induction and sustaining of hyperalgesia and its relationship to the 
DPP4 requires further studies.  
 
Therapeutic potential of the DPP4 inhibitors 
Our study has demonstrated that DPP4 exists in the spinal cord and, similarly to that in higher brain area, its 
expression significantly increases during pathological conditions. Inhibitors of the enzyme do not affect acute 
nociceptive processing but can selectively block glial mechanisms that contribute to the development and 
maintenance of hyperalgesia both in inflammatory and neuropathic conditions. This raises the possibility that 
DPP4 inhibitors targeting the central nervous system could be an important antihyperalgesic and anti-
inflammatory component of new analgesics for the treatment of severe and persistent pain without serious side 
effects. 
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7) TABLES 
 
Antibody Species Dilution  Source Catalog No. 
CGRP guinea pig 1:5000 Bachem-Peninsula Laboratories T-5027 
DPP4 goat 1:500 Fischer Scientific-Novus Biological NB100-61658 
DPP4 mouse 1:500 Abcam ab119346 
GFAP mouse 1:100 Leica Biosystems-Novocastra NCL-GFAP-GA5 
IBA1 rabbit 1:500 Wako Pure Chemical Industries Ltd 019-19741 
MAP2 mouse 1:500 Sigma-Aldrich M9942 
NeuN mouse 1:1000 Merck-Millipore-Chemicon MAB377 
VGAT rabbit 1:1000 Synaptic Systems 131 002 
VGLUT2 guinea pig 1:5000 Merck-Millipore-Chemicon AB2251 
Synaptophysin mouse 1:1000 Leica Biosystems-Novocastra NCL-SYNAP-299 
     
Table 1.  Specifications of primary antibodies used for immunohistochemistry  
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8) FIGURE LEGENDS 
 
Figure 1. DPP4 mRNA and protein expression in the dorsal horn of control, carrageenan treated and 
neuropathic rats. DPP4 mRNA expression in the dorsal horn of the spinal cord assessed by qPCR (A) and in 
situ hybridization (B) did not show significant difference among the three experimental groups (mean±SEM, n=6-
9, one-way ANOVA, p=0.30 and p=0.21 for qPCR and ISH, respectively). In Western-blot experiments (C) goat 
DPP4 antibody labelled one lane at 110kDa in spinal cord, lung and pancreas lysates. Western-blot detection of 
DPP4 in the spinal dorsal horn samples taken from naive, inflamed and neuropathic animals (D) and 
representative confocal images of transverse spinal dorsal horn sections obtained from rats of the three 
experimental groups and stained by mouse DPP4 antibody (E). Significantly increased DPP4 protein levels were 
detected in carrageenan-induced inflammation measured both by Western-blotting (F) and quantitative 
immunohistochemistry (G). (Values are given as mean±SEM, n=7-10, one-way ANOVA followed by Holm-
Sidac post hoc test: p=0.023 for Western blot experiments and one-way ANOVA with Student-Neuman-Keuls 
post hoc test: p=0.016 for densitometry). 
 
Figure 2. DPP4 immunoreactivity of different cell types in the spinal dorsal horn. DPP4-immunoreactive 
puncta appeared in Nissl stained neurons (row A), GFAP labelled astrocytes (row B) and IBA1 positive microglial 
cells (row C). Co-staining with mouse monoclonal antibody against the full length rat CD26 protein (DPP4mo, 
column 2) and polyclonal goat DPP4 antibody that was raised against the synthetic peptide C-PPHFDKSKKYP 
representing the internal region of DPP4 (DPP4gt, column 3) labelled the same puncta in all three cell types 
demonstrating the specificity of the two antibodies (arrows). All the images are single optical sections. Scalebar: 
5 μm. 
 
Figure 3. DPP4 immunoreactivity in various types of axon terminals. DPP4 immunolabelling on MAP2-
stained dendritic surfaces was associated with synaptophysisn (SYN) indicating that not the dendrites but the 
axon terminals express the receptor (row A). DPP4 is expressed by the majority of peptidergic (CGRP-containing) 
C primary afferent terminals (row B) and coexpression of DPP4 with SYN and VGLUT2 (row C) or VGAT (row 
D) suggests that DPP4 is present both in excitatory and inhibitory nerve endings. All the images are single optical 
sections. Scalebar: 5 μm. 
 
Figure 4. DPP4 immunoreactivity in glial cells in control, inflamed and neuropathic animals. Representative 
confocal images of the spinal dorsal horn obtained from control (A), inflamed (B) and neuropathic (C) animals 
demonstrate that DPP4 is expressed predominantly by glial cells (arrows: microglia, arrowheads: astrocytes). All 
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the images are single optical sections. Scalebar: 10 μm. Integrated density values (D) demonstrate that the 
majority of DPP4-immunopositivity is related to GFAP-labelled astrocytes. A proportion of DPP4 labelling 
belongs to microgila and very few DPP4 is expressed by neuronal cell bodies. Inflammation significantly 
increased the DPP4 expression on astocytes but not on the other cell types. In contrast to inflammation DPP4 
density was significantly higher on microglia and lower in neurons during neuropathy (Kruskal-Wallis One way 
ANOVA on ranks, Dunn’s Method, p<0,001). 
 
Figure 5. Antihyperalgesic effect of DPP4 inhibitor IPI and vildagliptin in carrageenan-induced 
inflammation. (A) Antihyperalgesic effect of IPI has been completely abolished by co-administartion of CTAP, 
but (B) neither TIPP[Ψ] nor (C) gNTI altered IPI-evoked antihyperalgesia. (D) Antihyperalgesic effect of 
vildagliptin was significantly reduced by CTAP and (F) gNTI, but was completely eliminated when (E) TIPP[Ψ] 
was co-injected. Inhibitory effects of opioid antagonists on IPI and vildagliptin related antihyperalgesia are 
summarized on bar graphs (G) and (H) constructed from data recorded 210 min after i.t. drug application. 
Comparisons were made with two-way ANOVA, Bonferoni post hoc test; +: p<0.05; +++: p<0.001 (A-F) and 
one-way ANOVA followed by Dunnett’s post hoc test. ***: p<0.001 (G and H). Asterisks always indicate 
significant differences between the time-matching points of DPP4 inhibitor and DPP4 inhibitor+opioid 
antagonist curves. Data on each curves and bars are given as mean and SEM. 
 
Figure 6. Antinociceptive effects of the DPP4 inhibitor IPI and vildagliptin in chronic neuropathic 
condition induced by partial sciatic nerve ligation. DPP4 inhibitors were ineffective in dynamic plantar 
aesthesiometer (A and D) and noxious cold sensitivity (B and E) tests. In Randall-Selitto test, both IPI and 
vildagliptin had antihyperalgesic effect which was not antagonized by NTX (C and F). Maximal possible effects 
(MPE%) of DPP4 inhibitors alone or in combination with subtype specific opioid antagonists is given on bar 
graphs (G-I). Comparisons were made with two-way ANOVA, Bonferoni post hoc test; +: p<0.05; ++: p<0.01; 
+++: p<0.001 (A-F) and one-way ANOVA followed by Dunnett’s post hoc test; *: p<0.1 **: p<0.01 (G-I). Data 
on each curves and bars are given as mean and SEM. 
